2025-04-02
Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump
Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.
[...]Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
2025-03-24
Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients
Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance.Read more... [...]
2025-01-16
The best live TV streaming services to cut cable in 2025
Around ten years ago, as the price of cable rose to untenable heights, live TV streaming services arrived as the low-cost, contract-free antidote. The services are still blissfully easy to walk away f [...]
2025-03-27
Wegovy sales took a hit this year. Novo's CEO blames off-brand competition
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or compounded, versions of the treatment, according to the Danish pharma giantâ [...]
2025-03-27
Tesla’s sales slump opens ‘rare window’ for European EV makers
Tesla’s sales in Europe have plummeted by 42% this year, according to the latest figures from the European Automobile Manufacturers Association. Tesla’s slip came despite total EV sales on the con [...]
2025-03-24
SAP becomes Europe’s most valuable company, ASML holds fourth place
Just five months after surpassing ASML, German software giant SAP has overtaken Novo Nordisk to become Europe’s most valuable listed company. SAP’s shares rose 1.6% on Monday, bringing its market [...]
2025-03-07
Trump's federal Bitcoin reserve order leaves the crypto market unenthused
With US stocks unstable, consumer confidence in the economy plunging and whispers of a potential recession growing less muted, the economy under President Donald Trump's second term has been abou [...]